Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
| Revenue (TTM) | $9.81M |
| Gross Profit (TTM) | $-30.17M |
| EBITDA | $-46.96M |
| Operating Margin | -335.70% |
| Return on Equity | -271.40% |
| Return on Assets | -46.60% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.27 |
| Price-to-Book | 20.10 |
| Price-to-Sales (TTM) | 19.36 |
| EV/Revenue | 42.43 |
| EV/EBITDA | -6.94 |
| Quarterly Earnings Growth (YoY) | -74.70% |
| Quarterly Revenue Growth (YoY) | 16.50% |
| Shares Outstanding | $111.70M |
| Float | $70.44M |
| % Insiders | 1.40% |
| % Institutions | 0.39% |
Volatility is currently contracting
Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75.
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome.
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several solid tumors also give it some diversification beyond Monalizumab. PACIFIC-9 is IPHA's largest near-term catalyst, but AstraZeneca controls it, and IPHA is only eligible for milestone payments and royalties if it succeeds.
MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IPHA and any ticker you trade — then tracks every position and per-strategy win rate.
